Anti-GD2 chimeric antigen receptor T cell therapy - Sinobioway Cell Therapy

Drug Profile

Anti-GD2 chimeric antigen receptor T cell therapy - Sinobioway Cell Therapy

Alternative Names: CAR-GD2-modified T cells - Sinobioway Cell Therapy; GD2-specific Chimeric Antigen Receptor-modified T Cells - Sinobioway Cell Therapy; GD2-targeted CAR-T cells - Sinobioway Cell Therapy

Latest Information Update: 06 Oct 2016

Price : $50

At a glance

  • Originator Sinobioway Cell Therapy
  • Class Antineoplastics; Cell therapies; Gene therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Neuroblastoma

Most Recent Events

  • 01 Sep 2016 Phase-I/II clinical trials in Neuroblastoma (Second-line therapy or greater, In children, In infants, In adolescents) in China (Parenteral) (NCT02919046)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top